keyword
MENU ▼
Read by QxMD icon Read
search

metastatic testicular cancer

keyword
https://www.readbyqxmd.com/read/28296054/modified-retroperitoneal-lymph-node-dissection-for-postchemotherapy-residual-tumor-a-long-term-update
#1
Jane S Cho, Hristos Z Kaimakliotis, K Clint Cary, Timothy A Masterson, Stephen Beck, Richard Foster
OBJECTIVES: To update previously reported outcomes of modified template postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in appropriately selected patients with metastatic non-seminomatous germ cell tumor (NSGCT). Our previous report was criticized for short follow-up. Herein, we provide a long-term update on this cohort. MATERIALS AND METHODS: One hundred patients with normal serum markers after cisplatin-based chemotherapy and residual retroperitoneal tumor underwent modified PC-RPLND between 1991 and 2004...
March 13, 2017: BJU International
https://www.readbyqxmd.com/read/28271048/abscessed-inguinal-metastasis-of-testicular-tumor-case-report
#2
Diego Barreiro, Fernando Blanco, Maria Laura Parise, Matias Caradonti, Francisco Castro, Norberto Lafos
The testicular tumor metastatic spread via the lymphatic system, and the anatomical distribution of this, finds his target in the retroperitoneal nodes. Male patient 28 years old with a history of bilateral orchidopexy is presented. It was performed a left orchiectomy and a biopsy of the ulcerated right inguinal mass, with diagnosis of malignant teratoma. Metastatic testicular tumors in inguinal nodes are extremely rare. However, we believe that in patients with a history of scrotal surgeries and inguinal mass, must suspect for a testicular cancer...
May 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28249598/the-prognostic-utility-of-the-transcription-factor-srf-in-docetaxel-resistant-prostate-cancer-in-vitro-discovery-and-in-vivo-validation
#3
D J Lundon, A Boland, M Prencipe, G Hurley, A O'Neill, E Kay, S T Aherne, P Doolan, S F Madden, M Clynes, C Morrissey, J M Fitzpatrick, R W Watson
BACKGROUND: Docetaxel based therapy is one of the first line chemotherapeutic agents for the treatment of metastatic castrate-resistant prostate cancer. However, one of the major obstacles in the treatment of these patients is docetaxel-resistance. Defining the mechanisms of resistance so as to inform subsequent treatment options and combinations represents a challenge for clinicians and scientists. Previous work by our group has shown complex changes in pro and anti-apoptotic proteins in the development of resistance to docetaxel...
March 1, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28237180/plasma-cytokines-correlated-with-disease-characteristics-progression-free-survival-and-overall-survival-in-testicular-germ-cell-tumor%C3%A2-patients
#4
Daniela Svetlovska, Viera Miskovska, Dana Cholujova, Paulina Gronesova, Silvia Cingelova, Michal Chovanec, Zuzana Sycova-Mila, Jana Obertova, Patrik Palacka, Jan Rajec, Katarina Kalavska, Vanda Usakova, Jan Luha, Dalibor Ondrus, Stanislav Spanik, Jozef Mardiak, Michal Mego
BACKGROUND: Cytokines are the communicators of immune system and are involved in all immune responses. The aim of this study was to assess the correlation among plasma cytokines, patient and tumor characteristics, and clinical outcome in chemonaive testicular germ-cell tumor (TGCT) patients. PATIENTS AND METHODS: This study included 92 metastatic chemotherapy-naive TGCT patients treated with platinum-based chemotherapy from July 2010 to March 2014. Plasma was isolated before first administration of chemotherapy, and the concentration of 51 plasma cytokines were analyzed using multiplex bead arrays...
February 8, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28220447/current-management-of-refractory-germ-cell-tumors-and-future-directions
#5
REVIEW
J Clayton Allen, Austin Kirschner, Kristen R Scarpato, Alicia K Morgans
PURPOSE OF REVIEW: We review current management strategies for patients with relapsed and refractory germ cell tumors (GCTs), defined as relapsed or persistent disease following at least one line of cisplatin-based chemotherapy. Additionally, we discuss future directions in the management of these patients. RECENT FINDINGS: Recent studies involving targeted therapies have been disappointing. Nevertheless, studies of the management of refractory germ cell cancer are ongoing, with a focus on optimal utilization of high-dose chemotherapy and autologous stem cell transplant, as well as the role of immune checkpoint inhibitors in refractory germ cell tumors...
February 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28163811/retroperitoneal-hematoma-following-radical-orchiectomy-two-cases
#6
Rachel Glicksman, Robert J Hamilton, Peter Chung
Treatment of testicular cancer is dependent on the stage of disease at presentation. Stage 1 testicular cancer is treated with radical orchiectomy, followed by active surveillance, radiotherapy, or chemotherapy. Occasionally, unusual and unexpected postoperative changes can be seen on computed tomography (CT), and may raise concern for metastatic disease. Here, we present two cases of testicular cancer patients who developed retroperitoneal hematomas post-radical orchiectomy, one as a classical clinical presentation, and the other as an atypical radiological entity only...
January 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28153774/patterns-of-care-and-survival-outcomes-for-adolescent-and-young-adult-patients-with-testicular-seminoma-in-the-united-states-a-national-cancer-database-analysis
#7
William Stokes, Arya Amini, Paul D Maroni, Elizabeth R Kessler, Claire Stokes, Carrye R Cost, Brian S Greffe, Timothy P Garrington, Arthur K Liu, Nicholas G Cost
INTRODUCTION: Testicular germ cell tumors (GCTs) are the most common solid tumor among adolescent and young adult (AYA) males. AYA patients with GCTs most typically have non-seminoma compared with seminoma, and accordingly there are fewer data reported on the AYA experience with testicular seminoma. OBJECTIVE: To evaluate national trends in postoperative treatment and overall survival (OS) outcomes in testicular seminoma by age group, specifically comparing AYAs with older adults...
January 17, 2017: Journal of Pediatric Urology
https://www.readbyqxmd.com/read/28113097/the-immune-infiltrate-in-prostate-bladder-and-testicular-tumors-an-old-friend-for-new-challenges
#8
REVIEW
Cinzia Solinas, Nieves Martinez Chanzá, Ahmad Awada, Mario Scartozzi
In genito-urinary tumors immunotherapy has been administered for a long time: Calmette-Guèrin Bacillus as adjuvant treatment in high risk patients with non muscle invasive urothelial bladder cancer and interleukin-2 and interferon-α in metastatic kidney cancer. The vaccine Sipuleucel-T has been approved by United States Food and Drug Administration for the treatment of castration resistant prostate cancer patients with asymptomatic or minimally symptomatic disease, given the 22% reduction of mortality risk in this group...
February 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28111042/-immunotherapy-in-uropathology
#9
Virginie Verkarre, Hélène Roussel, Clémence Granier, Eric Tartour, Yves Allory
The algorithms for treatment of metastatic cancers are evolving due to positive results obtained with immunotherapy. Therapeutics approaches to stimulate the immune system have already been used in the treatment of kidney and bladder cancer, such as the administration of cytokines and BCG therapy, confirming the immunogenicity of these tumors. The aim of immunotherapies is not only to activate the immune system against tumor cells, but also to take into account the tumor-induced suppressive microenvironment, in particular by removing the anergy of T-cell lymphocytes, and by targeting the co-stimulation inhibitors molecules...
February 2017: Annales de Pathologie
https://www.readbyqxmd.com/read/28071636/epidemiology-of-male-seminomatous-and-nonseminomatous-germ-cell-tumors-and-response-to-first-line-chemotherapy-from-a-tertiary-cancer-center-in-india
#10
A Joshi, S Zanwar, N Shetty, V Patil, V Noronha, G Bakshi, G Prakash, S Menon, K Prabhash
INTRODUCTION: Unlike the developed countries, there is a lack of good epidemiologic data for testicular germ cell tumors (GCTs) in India with majority presenting in advanced stage. This study aims to elaborate on the epidemiology of testicular GCTs and response to standard first-line chemotherapy (CT). METHODS: GCTs treated at our center from January 2013 to June 2014 were retrospectively analyzed. Patients underwent orchidectomy either outside or at our hospital...
April 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28058004/testicular-cancer-in-down-syndrome-with-spinal-cord-metastases
#11
Turky Almouhissen, Hattan Badr, Bassam AlMatrafi, Noor Alessa, Anmar Nassir
A 22-year-old male patient with Down syndrome was referred to our hospital with a vast left testicular mass. He underwent a left radical inguinal orchiectomy, and a histopathological examination of the mass showed a yolk sac tumor invading the epididymis. The patient was discharged in a satisfactory condition. Sixteen days later, the patient presented again complaining of lower limb weakness. Magnetic resonance imaging of the spine showed metastatic lesions compressing the dorsal spine, and he underwent emergency surgical decompression...
October 2016: Urology Annals
https://www.readbyqxmd.com/read/28026145/the-bromodomain-inhibitor-jq1-triggers-growth-arrest-and-apoptosis-in-testicular-germ-cell-tumours-in-vitro-and-in-vivo
#12
Sina Jostes, Daniel Nettersheim, Martin Fellermeyer, Simon Schneider, François Hafezi, Friedemann Honecker, Valerie Schumacher, Matthias Geyer, Glen Kristiansen, Hubert Schorle
Type II testicular germ cell cancers (TGCT) are the most frequently diagnosed tumours in young men (20-40 years) and are classified as seminoma or non-seminoma. TGCTs are commonly treated by orchiectomy and chemo- or radiotherapy. However, a subset of metastatic non-seminomas (embryonal carcinomas) displays only incomplete remission or relapse and requires novel treatment options. Recent studies have shown effective application of the small-molecule inhibitor JQ1 in tumour therapy, which interferes with the function of 'bromodomain and extraterminal (BET)' proteins...
December 27, 2016: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/28002522/primary-retroperitoneal-seminoma-embryology-histopathology-and-treatment-particularities
#13
Constantin Virgil Gîngu, Mihaela Mihai, Cătălin Baston, Mugurel Alexandru Crăsneanu, Alexandru Vladimir Dick, Vlad Olaru, Ioanel Sinescu
INTRODUCTION: Retroperitoneal seminoma is a very rare form of cancer, with embryological origin represented by primordial germ cells from the urogenital ridges left behind during the fetal development. Extragenital germ cell tumors can also occur in the mediastinum or the pineal gland. The aim of this paper is to outline the particularities and draw embryological, histopatological and treatment conclusions regarding extragonadal germ cell tumors. PATIENT AND METHODS: A 43-year-old patient without any additional pathology was admitted for anemia of unknown etiology...
2016: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
https://www.readbyqxmd.com/read/27915468/clinical-characteristics-of-testicular-germ-cell-tumors-in-patients-aged-50-years-and-older-a-large-scale-study-from-the-cancer-registration-committee-of-the-japanese-urological-association
#14
Taketo Kawai, Yoshinori Tanaka
OBJECTIVES: To determine the characteristics of testicular germ cell tumors in older patients. METHODS: A testicular cancer survey was carried out by the Japanese Urological Association in 2011 to register the testicular cancers diagnosed in 2005 and 2008. The survey included age, presenting symptoms, physical examination findings, tumor markers, histopathology, clinical stage, treatment and clinical outcomes. These factors were compared between patients aged ≥50 years and those aged <50 years at diagnosis...
December 4, 2016: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/27905446/genomic-evolution-and-chemoresistance-in-germ-cell-tumours
#15
Amaro Taylor-Weiner, Travis Zack, Elizabeth O'Donnell, Jennifer L Guerriero, Brandon Bernard, Anita Reddy, G Celine Han, Saud AlDubayan, Ali Amin-Mansour, Steven E Schumacher, Kevin Litchfield, Clare Turnbull, Stacey Gabriel, Rameen Beroukhim, Gad Getz, Scott L Carter, Michelle S Hirsch, Anthony Letai, Christopher Sweeney, Eliezer M Van Allen
Germ-cell tumours (GCTs) are derived from germ cells and occur most frequently in the testes. GCTs are histologically heterogeneous and distinctly curable with chemotherapy. Gains of chromosome arm 12p and aneuploidy are nearly universal in GCTs, but specific somatic genomic features driving tumour initiation, chemosensitivity and progression are incompletely characterized. Here, using clinical whole-exome and transcriptome sequencing of precursor, primary (testicular and mediastinal) and chemoresistant metastatic human GCTs, we show that the primary somatic feature of GCTs is highly recurrent chromosome arm level amplifications and reciprocal deletions (reciprocal loss of heterozygosity), variations that are significantly enriched in GCTs compared to 19 other cancer types...
November 30, 2016: Nature
https://www.readbyqxmd.com/read/27867337/oligometastatic-growing-teratoma-syndrome-a-case-for-an-aggressive-surgical-approach
#16
William S Gange, Robert H Blackwell, John Biemer, Güliz A Barkan, Maria M Picken, Marcus L Quek
Growing teratoma syndrome is an infrequent presentation of testicular cancer. We present a case of growing teratoma syndrome in a patient who initially presented with clinical stage I nonseminomatous testicular germ cell tumor, who subsequently developed large volume oligometastases to the retroperitoneum, thorax, and thigh. Despite two regimens of chemotherapy, his disease progressed. Complete surgical extirpation of all gross tumors confirmed mature teratoma. An aggressive surgical approach, including postchemotherapy resection of all known metastatic sites, can provide long-term disease-free survival...
October 2016: Current Urology
https://www.readbyqxmd.com/read/27846929/-ccafu-french-national-guidelines-2016-2018-on-testicular-germ-cell-tumors
#17
X Durand, A Fléchon, T Murez, L Rocher, P Camparo, N Morel-Journel, P-H Savoie, L Ferretti, P Sèbe, A Méjean
INTRODUCTION: The purpose of the oncologic comitee of the french association of urology was to establish guidelines proposed by the external genital organ group, for the diagnosis, treatment and follow-up of the germ cell tumours of the testis. MATERIAL AND METHODS: The multidisciplinary working group studied 2013 guidelines, exhaustively reviewed the literature, and evaluated references and their level of proof in order to attribute grades of recommandation. RESULTS: The initial workup of testicular cancer is based on clinical, laboratory (AFP, total hCG, LDH) and imaging assessment (scrotal ultrasound and chest, abdomen and pelvis computed tomography)...
November 2016: Progrès en Urologie
https://www.readbyqxmd.com/read/27831507/surgical-management-of-complex-residual-masses-following-systemic-chemotherapy-for-metastatic-testicular-germ-cell-tumours
#18
A Heidenreich, F Haidl, P Paffenholz, Ch Pape, U Neumann, D Pfister
BACKGROUND: Post-chemotherapy retroperitoneal lymphadenectomy (PC-RPLND) represents the treatment of choice in patients with residual masses following chemotherapy for metastatic germ cell tumours. Involvement of major retroperitoneal vessels or thoracic/lumbar spine is rare and challenging but needs complete resection for curative intent. We report on our experience in the management of such complex cases. PATIENTS AND METHODS: A total of 185 patients underwent PC-RPLND and we identified 25 (13...
November 9, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27733750/can-we-predict-chemotherapy-response-in-patients-with-metastatic-testicular-cancer-role-of-thrombocytosis-as-a-novel-marker
#19
Mehmet I Gokce, Murat Mermerkaya, Evren Süer, Faraj Afandiyev, Sümer Baltaci
BACKGROUND: Primary treatment of choice for advanced germ cell tumors is 3 to 4 cycles of combination PEB chemotherapy. Although most patients treated for advanced germ cell tumors (GCT) will be cured, approximately 30% will fail to achieve a durable complete response (CR). Thrombocytosis has been found to be related with significantly shorter survival in many cancers. However, its role in testicular cancer patients has not been studied previously. The objective of this study was to investigate the relationship between thrombocytosis and chemotherapy response in patients with metastatic testicular cancer...
October 12, 2016: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
https://www.readbyqxmd.com/read/27732978/prevalence-of-late-onset-hypogonadism-in-men-with-localized-and-metastatic-renal-cell-carcinoma
#20
Bernhard Ralla, Ahmed Magheli, Ingmar Wolff, Barbara Erber, Irena Goranova, Frank Friedersdorff, Stefan Hinz, Carsten Kempkensteffen, Kurt Miller, Jonas Busch
BACKGROUND: Cancer-related fatigue is a common symptom in patients with renal cell carcinoma (RCC) and can be similar to the fatigue found in late-onset hypogonadism (LOH). The aim of this study was to investigate the prevalence of LOH in patients with localized RCC (loRCC) and metastatic RCC (mRCC) disease under targeted therapy (TT) and compare the results to findings of epidemiologic studies. METHODS: A total of 51 mRCC patients under TT and 33 patients with loRCC undergoing nephrectomy were included...
2017: Urologia Internationalis
keyword
keyword
76461
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"